Covered recipient · General Payments record
VIVIAN DURU
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2023–2024
$451.53
- Reported across 24 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $265.81 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $91.67 | 5 |
| Acerta Pharma LLC | $31.58 | 2 |
| Merck Sharp & Dohme Corporation | $24.92 | 1 |
| DEXCOM, INC. | $19.58 | 1 |
| ABBVIE INC. | $18.77 | 1 |
| Astellas Pharma US Inc | $18.00 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $17.82 | 1 |
| GlaxoSmithKline, LLC. | $15.34 | 1 |
| Medtronic, Inc. | $14.25 | 1 |
| Lilly USA, LLC | $13.88 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.77 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107053285 | CMS |
| Astellas Pharma US Inc | $18.00 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139537716 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.50 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105378582 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.08 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104232325 | CMS |
| Dexcom, Inc. | $19.58 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153391544 | CMS |
| GlaxoSmithKline, LLC. | $15.34 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115978814 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $17.82 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146769321 | CMS |
| Lilly USA, LLC | $13.88 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135984876 | CMS |
| Medtronic, Inc. | $14.25 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116948772 | CMS |
| Merck Sharp & Dohme LLC | $24.92 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141755492 | CMS |
| PFIZER INC. | $16.23 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131282157 | CMS |
| PFIZER INC. | $21.60 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131669904 | CMS |
| PFIZER INC. | $17.75 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131889607 | CMS |
| PFIZER INC. | $17.23 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132127921 | CMS |
| PFIZER INC. | $18.86 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131245785 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.